A team of researchers has discovered that changes in speed of electrical signals across the optic nerves may reflect recovery of the myelin loss during multiple sclerosis.
Browsing: Demyelinating disease
A preclinical study in mice has revealed that a specific miRNA could target and modulate the gut microbiome with precision, holding potential as a new treatment option for multiple sclerosis.
NHS England have approved the use of cannabis-based medicines for the first time. Epidyolex can now be prescribed to children with severe epilepsy syndromes and Sativex can be prescribed to individuals with multiple sclerosis.
At the Glial meeting in Portugal, we had the fantastic opportunity of interviewing Ana Mendanha Falcão about her research on oligodendrocytes and her experiences on acquiring viable glial cells from adult brain tissues.
At the Glial meeting in Portugal, we had the fantastic opportunity of interviewing Pascale Eede and Verena Haage about their research with astrocytes and microglia, as well as their experiences on acquiring viable glial cells from adult brain tissues.
In this interview from the Video Journal of Biomedicine, Hannah Brown (Ipsos Healthcare, London, UK) discusses physician and patient treatment decision-making for relapsing–remitting multiple sclerosis.
What have been the biggest headlines in industry this week? Take a look at our highlights including positive news about two monoclonal antibodies for relapsing multiple sclerosis and neuromyelitis optica spectrum disorder.
Chronic active lesions (‘smoldering’ spots) may be a hallmark for progressive forms of multiple sclerosis, a recently published study suggests.
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
MRI scans of individuals living with multiple sclerosis could predict how the disease will progress in the following years. This information could potentially be useful when considering treatment options.